6952-94-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Phenyl-4-piperidinecarboxaldehyde is used as a precursor in the synthesis of various active pharmaceutical ingredients. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Chemical Industry:
4-Phenyl-4-piperidinecarboxaldehyde serves as a building block for the preparation of heterocyclic compounds, which are essential components in many chemical products and materials.
Used in Organic Synthesis:
As a reagent in organic synthesis, 4-Phenyl-4-piperidinecarboxaldehyde enables the creation of a wide range of chemical products, showcasing its versatility and importance in the field of chemistry.

InChI:InChI=1/C12H15NO/c14-10-12(6-8-13-9-7-12)11-4-2-1-3-5-11/h1-5,10,13H,6-9H2

Upstream product

• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 

Downstream Products

• 93990-39-7 1-(2-morpholin-4-yl-ethyl)-4-phenyl-piperidine-4-carbaldehyde 
• 167853-54-5 4-[3-(3,5-Bis-trifluoromethyl-phenyl)-3-oxo-propyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 167853-55-6 4-[3-(3,5-Bis-trifluoromethyl-phenyl)-3-hydroxy-propyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

4,4-Disubstituted piperidine high-affinity NK1 antagonists: Structure- activity relationships and in vivo activity

Previously reported studies from these laboratories described the design of a novel series of high-affinity NK1 antagonists based on the 4,4- disubstituted piperidine ring system. Further structure-activity studies have now established that for high NK1 affinity the benzyl ether side chain must be 3,5-disubstituted and highly lipophilic, the optimal side chain being the 3,5-bis(trifluoromethyl)benzyl ether, 12 (hNK1 IC50 = 0.95 nM). Additional studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (38) (hNK1 IC50 = 5.3 nM) and sulfonyl (39) (hNK1 IC50 = 5.7 nM) derivatives. Following preliminary pharmacokinetic analysis, two compounds (32 and 43) were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).